This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Learn about ATTR-CM and uncover the differences between hereditary and wild-type ATTR-CM

Learn about the red flags that may raise suspicion of and techniques used to diagnose ATTR-CM

Explore a range of educational resources to support the diagnosis of ATTR-CM

Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Current standard of care and emerging treatment strategies

In February 2020, the European Commission granted marketing authorisation for tafamidis, a transthyretin stabiliser, available as a once-daily 61 mg oral capsule1, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Whilst there is a licence for Vyndaqel for ATTR-CM in the UK, there is not currently funded NHS access.

Other available treatment options for ATTR-CM are aimed at symptom management, supportive care including pain management, nutritional and mobility support and mitigation of the effects of the disease on other organs.2

Additional treatment options are currently under investigation. Emerging treatment strategies are aimed at reducing the formation of the amyloid fibrils by targeting different stages of their development.3

Note: These are investigational approaches, and no conclusions can be made about safety and efficacy. 

Explore more

See other educational resources available

 Explore more

  1. Vyndaqel Summary of Product Characteristics for GB available at and Vyndaqel Summary of Product Characteristics for NI available at​​​​​​​
  2. Hawkins PN, Ando Y, Dispenzen A et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015; 47: 625–638.
  3. Ruberg FL, Grogan M, Hanna M et al. Transthyretin Amyloid Cardiomyopathy. JACC State-of-the-Art Review. JACC. 2019; 73(22): 2872–2891.
  4. Maurer MS, Elliott P, Comenzo R et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017; 135(14): 1357–1377.
  5. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018; 33(5): 571–579.
  6. Judge DP, Heitner SB, Falk RH et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019; 74(3): 285–295.
PP-VYN-GBR-0925. December 2021

 Quick Links

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. October 2020

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?